TUCANAT 150MG TABS 60'S

About

Tucatinib is an oral tyrosine kinase inhibitor specifically designed to target human epidermal growth factor receptor 2 (HER2). It selectively inhibits HER2 and, to a lesser extent, epidermal growth factor receptor (EGFR) phosphorylation, thereby blocking downstream signaling pathways that promote cell growth and survival in HER2-positive cancers. Unlike some other HER2 inhibitors, tucatinib demonstrates high selectivity for HER2, which contributes to its efficacy and a more favorable safety profile. Its ability to cross the blood-brain barrier is particularly significant, making it an important treatment option for patients with HER2-positive metastatic breast cancer, especially those with brain metastases.

This medication is typically used in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. It offers a targeted approach to therapy, improving progression-free survival and overall survival in this challenging patient population.

Uses

• Treatment of HER2-positive metastatic breast cancer.
• Used in combination with trastuzumab and capecitabine.
• Effective for patients with brain metastases.
• For patients who have received prior anti-HER2 therapies.

Directions For Use

Take orally twice daily, approximately 12 hours apart, with or without food. Swallow tablets whole.

Benefits

• Targets HER2-positive breast cancer specifically.
• Effective in patients with brain metastases.
• Improves progression-free survival.
• Offers a targeted therapy approach.
• Can be used after prior anti-HER2 treatments.
• Generally well-tolerated in combination.

Side Effects

• Diarrhea
• Nausea
• Fatigue
• Vomiting
• Stomatitis
• Palmar-plantar erythrodysesthesia syndrome
• Abnormal liver function tests
• Rash
• Decreased appetite
• Anemia
• Headache
• Neutropenia

Safety Measures

• Alcohol - No specific contraindication, but alcohol may exacerbate gastrointestinal side effects like diarrhea or nausea.
• Pregnancy - May cause fetal harm; avoid use during pregnancy. Advise women of reproductive potential to use effective contraception.
• Breastfeeding - It is unknown if tucatinib passes into breast milk; advise against breastfeeding during treatment and for 1 week after the last dose.
• Liver - Use with caution in patients with severe hepatic impairment; dose adjustment may be necessary. Monitor liver function closely.
• Kidney - No dose adjustment is required for mild to moderate renal impairment; data for severe impairment is limited.
• Lung - No specific contraindications; however, monitor for new or worsening pulmonary symptoms, though rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.